Abstract P4-04-09: New oral SERD elacestrant (RAD1901) shows efficacy in breast cancer models harbouring ESR1 mutations and enhances the antiproliferative activity of mTORC1 and CDK4/6 inhibitors
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs17-p4-04-09
Abstract: Background: Targeting estrogen receptor (ER) signalling is the main therapeutic option for ER+ breast cancer (BC). However, over 30% of patients relapse with endocrine resistance emphasising the need for improved therapeutic strategies. The prevalence of… read more here.
Keywords: elacestrant; cdk4; breast cancer; cancer ... See more keywords